May 5, 2025 | Legislative, News, Pharmacy, Pharmacy Benefits Manager (PBM), State legislation
On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...
Mar 24, 2025 | Drug costs, Lawsuits, News, Pharmacy Benefits Manager (PBM), Prescription
Current and former employees are suing the financial services firm JPMorgan for allowing inflated drug prices through its partnership with pharmacy benefits manager (PBM) CVS Caremark. The plaintiffs claim that poor PBM oversight led to unnecessarily high prescription...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
Jan 10, 2025 | Drug costs, Drug reimportation, News
Pharmaceutical companies are planning to increase prices on over 250 brand-name medications in the United States at the beginning of 2025, according to an analysis by health care research firm 3 Axis Advisors. That’s a notable drop from last January, during...
Aug 30, 2024 | Compliance, Employee Retirement Income Security Act (ERISA), Legislative, News, Regulatory
50 years ago – on September 2, 1974 – ERISA was signed into law by President Gerald R. Ford. The Employee Retirement Income Security Act has had a profound impact on how health benefits are provided to most working Americans. Despite its impact, the legislation...
Aug 2, 2024 | Cancer, Colon Cancer, Colonoscopy, Food and Drug Administration (FDA), News, Preventive Care, Research, Wellness
On July 29, the Food and Drug Administration approved a first-of-its-kind blood test determined to be 83% effective at detecting colon cancer. Called Shield, the noninvasive test was authorized for use by people aged 45 and older with an “average risk” of the...
